Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial.
Blandine Gatta CherifiKamel MohammediTanguy CariouChristine PoitouPhilippe A TouraineGerald RaverotThierry BruePhilippe ChansonFrédéric IllouzSolange GrunenwaldOlivier ChabreEmmanuel SonnetThomas CunyJerôme BertheratSébastien CzernichowEric FrisonAntoine TabarinPublished in: European journal of endocrinology (2024)
Combined with intensive lifestyle interventions, a 26-week treatment with exenatide was not demonstrated superior to placebo to treat craniopharyngioma-related obesity.
Keyphrases
- weight loss
- double blind
- bariatric surgery
- roux en y gastric bypass
- placebo controlled
- gastric bypass
- metabolic syndrome
- physical activity
- insulin resistance
- weight gain
- phase iii
- clinical trial
- type diabetes
- glycemic control
- study protocol
- high fat diet induced
- skeletal muscle
- body mass index
- drug induced
- combination therapy